Business Summary

PYC Therapeutics Limited is an Australia-based pre-clinical-stage biotechnology company, which offers ribonucleic acid (RNA) therapeutics to meet unmet needs in disease. The Company has RNA targeted therapeutics design capabilities to deliver technologies based on cell penetrating peptides (CPPs) and peptide conjugated phosphorodiamidate morpholino oligomer (PPMOs). The Company develops a pipeline of therapies, including two programs, which are focused on inherited eye diseases and preclinical discovery programs, which are focused on neurodegenerative and kidney diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA). Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The Company's discovery and laboratory operations are located in Australia.